Yun Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yun Luo has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Ying Zhang
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, China
7 shared publications- Chun Cao
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 shared publications Han-Qing Zeng
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, China
3 shared publicationsJian-Chuan Deng
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, China
3 shared publicationsChun Cao
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Chongqing 400010, China
2 shared publicationsShi-Feng Lou
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications
Latest Publications
- 12 August 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
MRI ‐Based Vertebral Bone Quality Score and Paravertebral Muscle Parameters for Identifying Osteoporotic Vertebral Compression Fractures
Background: Osteoporotic vertebral compression fractures (OVCFs) are prevalent but frequently remain unrecognized. While bone mineral density (BMD) is the primary assessment tool, MRI‐based parameters associated with bone and muscle quality may offer additional value, yet sex‐specific analyses are limited, despite sex differences in incidence and hormones. Purpose: To explore the associations between MRI‐based vertebral bone quality (VBQ) score, psoas muscle index (PMI), and paravertebral muscle fat infiltration (FI) fraction with OVCFs, and to assess the potential diagnostic performance of MRI parameters across sexes. Study Type: Retrospective. Population: 260 subjects (≥ 50 years); 130 OVCF patients (73.0 years (67.0–80.0), 89 females) and 130 non‐fracture (NF) patients (64.5 years (58.0–73.0), 76 females). Field Strength and Sequences: 3 T and 1.5 T. T1‐weighted TSE and T2‐weighted TSE (Siemens) and T1‐weighted FSE and T2‐weighted FSE (United Imaging). Assessment: VBQ was calculated on sagittal T1‐weighted MRI; PMI and FI were quantified on axial T2‐weighted MRI at the L3 endplate by ImageJ. BMD was derived from CT using QCT PRO software. Two trained observers, blinded to clinical data, performed all MRI measurements. Statistical Tests: Significance level was set at p < 0.05. t ‐test/Mann–Whitney U test, chi‐squared test ( χ 2 ), Spearman's rank correlation coefficient, multivariate logistic regression, receiver operating characteristic (ROC) curve analysis with area under the curve (AUC). Bootstrap resampling (1000 iterations) for internal validation. Results: The OVCF group exhibited significantly elevated VBQ (3.71 ± 0.55 vs. 3.25 ± 0.58) and FI (24.11% (21.66–28.92) vs. 20.31% (18.90–22.14)), while PMI (3.42 ± 1.02 vs. 4.08 ± 1.14) and BMD (55.82 mg/cm 3 (38.75–70.90) vs. 89.24 mg/cm 3 (67.80–110.00)) were reduced. FI was independently associated with OVCFs exclusively in females (OR = 1.566). The combined MRI model (VBQ + FI + PMI) yielded a significantly higher AUC in females (AUC = 0.896) than in males (AUC = 0.720). Data Conclusion: VBQ, PMI, and FI reveal significant sex‐specific correlations with OVCFs. The multi‐parametric MRI model shows considerable potential as a diagnostic aid for OVCFs in individuals aged over 50, particularly in females. Level of Evidence: 4. Technical Efficacy Stage: 2 (Diagnostic Accuracy).
- 12 August 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
MRI ‐Based Vertebral Bone Quality Score and Paravertebral Muscle Parameters for Identifying Osteoporotic Vertebral Compression Fractures
Background: Osteoporotic vertebral compression fractures (OVCFs) are prevalent but frequently remain unrecognized. While bone mineral density (BMD) is the primary assessment tool, MRI‐based parameters associated with bone and muscle quality may offer additional value, yet sex‐specific analyses are limited, despite sex differences in incidence and hormones. Purpose: To explore the associations between MRI‐based vertebral bone quality (VBQ) score, psoas muscle index (PMI), and paravertebral muscle fat infiltration (FI) fraction with OVCFs, and to assess the potential diagnostic performance of MRI parameters across sexes. Study Type: Retrospective. Population: 260 subjects (≥ 50 years); 130 OVCF patients (73.0 years (67.0–80.0), 89 females) and 130 non‐fracture (NF) patients (64.5 years (58.0–73.0), 76 females). Field Strength and Sequences: 3 T and 1.5 T. T1‐weighted TSE and T2‐weighted TSE (Siemens) and T1‐weighted FSE and T2‐weighted FSE (United Imaging). Assessment: VBQ was calculated on sagittal T1‐weighted MRI; PMI and FI were quantified on axial T2‐weighted MRI at the L3 endplate by ImageJ. BMD was derived from CT using QCT PRO software. Two trained observers, blinded to clinical data, performed all MRI measurements. Statistical Tests: Significance level was set at p < 0.05. t ‐test/Mann–Whitney U test, chi‐squared test ( χ 2 ), Spearman's rank correlation coefficient, multivariate logistic regression, receiver operating characteristic (ROC) curve analysis with area under the curve (AUC). Bootstrap resampling (1000 iterations) for internal validation. Results: The OVCF group exhibited significantly elevated VBQ (3.71 ± 0.55 vs. 3.25 ± 0.58) and FI (24.11% (21.66–28.92) vs. 20.31% (18.90–22.14)), while PMI (3.42 ± 1.02 vs. 4.08 ± 1.14) and BMD (55.82 mg/cm 3 (38.75–70.90) vs. 89.24 mg/cm 3 (67.80–110.00)) were reduced. FI was independently associated with OVCFs exclusively in females (OR = 1.566). The combined MRI model (VBQ + FI + PMI) yielded a significantly higher AUC in females (AUC = 0.896) than in males (AUC = 0.720). Data Conclusion: VBQ, PMI, and FI reveal significant sex‐specific correlations with OVCFs. The multi‐parametric MRI model shows considerable potential as a diagnostic aid for OVCFs in individuals aged over 50, particularly in females. Level of Evidence: 4. Technical Efficacy Stage: 2 (Diagnostic Accuracy).
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50003
Mapping the research landscape of virtual reality and artificial intelligence in medical education evaluation: A bibliometric analysis
Background: Evaluation of medical education is essential for ensuring the quality of health professional training. However, conventional evaluation approaches often lack objectivity, scalability, and longitudinal assessment capacity. Virtual reality (VR) and artificial intelligence (AI) are increasingly integrated into medical education, yet their application in educational evaluation has not been systematically characterized. Objective: To examine research trends, thematic evolution, and emerging directions in VR- and AI-enabled medical education evaluation, a bibliometric analysis was conducted. Methods: Publications indexed in the Web of Science Core Collection between January 1, 2015, and December 31, 2025, were retrieved using predefined search terms related to VR, AI, medical education, and evaluation. Eligible English-language articles and reviews were analyzed using CiteSpace (version 6.4.R2). Annual publication and citation trends, country collaboration patterns, and cited journals were assessed. Research themes and frontiers were examined through keyword co-occurrence, clustering, burst detection, and timeline analyses. Results: A total of 695 publications were included. Annual publications and citations increased steadily, with accelerated growth after 2020. The United States, Germany, China, England, and Canada produced the highest number of publications, whereas Belgium, Egypt, Sweden, Singapore, and Switzerland demonstrated high collaboration centrality. Influential cited journals were concentrated in medical education and simulation-based training domains. Keyword analyses identified major themes including surgical education, VR simulation, clinical reasoning, decision support, and residency and undergraduate education. Burst and timeline analyses indicated a progression from early simulation-based skill validation toward learner-centered performance evaluation and, more recently, quality-oriented and curriculum-level assessment. Conclusions: Research on VR- and AI-enabled medical education evaluation has expanded rapidly and evolved from technical skill assessment toward comprehensive, competency-oriented, and quality-focused evaluation. These findings highlight the growing role of emerging technologies in shaping future global medical education evaluation frameworks.
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50003
Open AccessMapping the research landscape of virtual reality and artificial intelligence in medical education evaluation: A bibliometric analysis
Background: Evaluation of medical education is essential for ensuring the quality of health professional training. However, conventional evaluation approaches often lack objectivity, scalability, and longitudinal assessment capacity. Virtual reality (VR) and artificial intelligence (AI) are increasingly integrated into medical education, yet their application in educational evaluation has not been systematically characterized. Objective: To examine research trends, thematic evolution, and emerging directions in VR- and AI-enabled medical education evaluation, a bibliometric analysis was conducted. Methods: Publications indexed in the Web of Science Core Collection between January 1, 2015, and December 31, 2025, were retrieved using predefined search terms related to VR, AI, medical education, and evaluation. Eligible English-language articles and reviews were analyzed using CiteSpace (version 6.4.R2). Annual publication and citation trends, country collaboration patterns, and cited journals were assessed. Research themes and frontiers were examined through keyword co-occurrence, clustering, burst detection, and timeline analyses. Results: A total of 695 publications were included. Annual publications and citations increased steadily, with accelerated growth after 2020. The United States, Germany, China, England, and Canada produced the highest number of publications, whereas Belgium, Egypt, Sweden, Singapore, and Switzerland demonstrated high collaboration centrality. Influential cited journals were concentrated in medical education and simulation-based training domains. Keyword analyses identified major themes including surgical education, VR simulation, clinical reasoning, decision support, and residency and undergraduate education. Burst and timeline analyses indicated a progression from early simulation-based skill validation toward learner-centered performance evaluation and, more recently, quality-oriented and curriculum-level assessment. Conclusions: Research on VR- and AI-enabled medical education evaluation has expanded rapidly and evolved from technical skill assessment toward comprehensive, competency-oriented, and quality-focused evaluation. These findings highlight the growing role of emerging technologies in shaping future global medical education evaluation frameworks.
- Open Access
- 8 July 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (10)
Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias
Treatment-refractory autoimmune cytopenias (AIC) including immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evans syndrome (ES) lack therapies providing durable remission. We conducted a retrospective cohort study of 22 adults with refractory primary AIC who received single low-dose daratumumab (100 mg, day 0) combined with rituximab (100 mg weekly ×4 doses) and glucocorticoids. Primary endpoints were overall response rate (ORR), complete response rate (CRR), relapse-free survival (RFS), and safety. Among participants (median age 63.0 years; 81.8% female), 95.5% achieved initial response (CRR 27.3%; partial response rate 68.2%) with median time-to-response 7 days. At median follow-up 322 days, sustained ORR was 81.8% with CRR 59.1%. with disease-specific rates: CRR/ORR of 60.0%/80.0% (AIHA), 60.0%/70.0% (ITP), and 57.1%/100.0% (ES). Cumulative CRR by subtype were 75% (AIHA), 80% (ITP), and 65.7% (ES) (P = 0.031). The median RFS was not reached during the follow-up period. Averse events occurred in 36.4% of patients, primarily infections (27.8%; herpesvirus, urinary/respiratory tract) and rash (9.1%); all resolved with intervention. In conclusion, this dual-pathway targeting regimen induced rapid, durable hematologic responses in refractory AIC with manageable toxicity. The single low-dose daratumumab approach demonstrates significant clinical feasibility, potentially redefining therapeutic paradigms for antibody-mediated autoimmune disorders.
- 8 July 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (10)
Open AccessSingle low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias
Treatment-refractory autoimmune cytopenias (AIC) including immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evans syndrome (ES) lack therapies providing durable remission. We conducted a retrospective cohort study of 22 adults with refractory primary AIC who received single low-dose daratumumab (100 mg, day 0) combined with rituximab (100 mg weekly ×4 doses) and glucocorticoids. Primary endpoints were overall response rate (ORR), complete response rate (CRR), relapse-free survival (RFS), and safety. Among participants (median age 63.0 years; 81.8% female), 95.5% achieved initial response (CRR 27.3%; partial response rate 68.2%) with median time-to-response 7 days. At median follow-up 322 days, sustained ORR was 81.8% with CRR 59.1%. with disease-specific rates: CRR/ORR of 60.0%/80.0% (AIHA), 60.0%/70.0% (ITP), and 57.1%/100.0% (ES). Cumulative CRR by subtype were 75% (AIHA), 80% (ITP), and 65.7% (ES) (P = 0.031). The median RFS was not reached during the follow-up period. Averse events occurred in 36.4% of patients, primarily infections (27.8%; herpesvirus, urinary/respiratory tract) and rash (9.1%); all resolved with intervention. In conclusion, this dual-pathway targeting regimen induced rapid, durable hematologic responses in refractory AIC with manageable toxicity. The single low-dose daratumumab approach demonstrates significant clinical feasibility, potentially redefining therapeutic paradigms for antibody-mediated autoimmune disorders.
- Open Access
- 26 May 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 48, 101263
Pegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study
- 26 May 2026
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 48, 101263
Open AccessPegfilgrastim versus filgrastim for chemo-mobilized stem cell collection in multiple myeloma: A retrospective real-world study
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Hematology
- Vol. 2026 (1) , 1212359
Successful Haploidentical Hematopoietic Stem Cell Transplantation for Chemotherapy‐Induced Aplastic Anemia in a Breast Cancer Survivor: A Case Report and Literature Review
Chemotherapy‐induced aplastic anemia (AA) is a rare but potentially life‐threatening complication in solid tumor treatment. While allogeneic hematopoietic stem cell transplantation (HSCT) is a recognized treatment for AA, haploidentical HSCT (haplo‐HSCT) for chemotherapy‐induced AA in solid tumor patient survivors remains largely unexplored. We report a unique case of successful haplo‐HSCT in a breast cancer survivor who developed AA following chemotherapy. In addition, we conducted a comprehensive literature review on chemotherapy‐induced AA in breast cancer patients and its management, with a focus on HSCT outcomes. This case demonstrates the potential efficacy of haplo‐HSCT in treating chemotherapy‐induced AA in breast cancer survivors. It highlights an important therapeutic option for this rare but severe complication, particularly when matched donors are unavailable. Our experience contributes valuable insights to the limited literature on managing this challenging clinical scenario.
- 1 January 2026
- Published by Wiley in Case Reports in Hematology
- Vol. 2026 (1) , 1212359
Open AccessSuccessful Haploidentical Hematopoietic Stem Cell Transplantation for Chemotherapy‐Induced Aplastic Anemia in a Breast Cancer Survivor: A Case Report and Literature Review
Chemotherapy‐induced aplastic anemia (AA) is a rare but potentially life‐threatening complication in solid tumor treatment. While allogeneic hematopoietic stem cell transplantation (HSCT) is a recognized treatment for AA, haploidentical HSCT (haplo‐HSCT) for chemotherapy‐induced AA in solid tumor patient survivors remains largely unexplored. We report a unique case of successful haplo‐HSCT in a breast cancer survivor who developed AA following chemotherapy. In addition, we conducted a comprehensive literature review on chemotherapy‐induced AA in breast cancer patients and its management, with a focus on HSCT outcomes. This case demonstrates the potential efficacy of haplo‐HSCT in treating chemotherapy‐induced AA in breast cancer survivors. It highlights an important therapeutic option for this rare but severe complication, particularly when matched donors are unavailable. Our experience contributes valuable insights to the limited literature on managing this challenging clinical scenario.
- 23 May 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (5) , e70277
Co‐Occurrence of Hemophilia and Ankylosing Spondylitis in a Pair of Identical Twins
- 23 May 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (5) , e70277
Co‐Occurrence of Hemophilia and Ankylosing Spondylitis in a Pair of Identical Twins
- 13 January 2023
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 55 (2) , 399-405
Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia associated with disseminated microvascular platelet-rich thrombus. Before the introduction of plasma therapy, acute TTP was almost universally fatal, which improved survival from < 10 to 80–90%. However, patients who survived an acute attack were at high risk for recurrence and long-term morbidity. It was reported that daratumumab can eradicate persistent ADAMTS13-inhibiting autoantibodies and restore ADAMTS13 activity in two patients with relapsed immune-mediated TTP without associated adverse drug reactions. Here we report a case series of patients with initial diagnosed acquired TTP treated with combination regimens containing daratumumab. All the patients achieved clinical response after the initial treatment. Three patients achieved clinical remission, one patient relapsed and one patient suffered an exacerbation during follow-up. The two patients were retreated with glucocorticoids, plasma exchange combined with daratumumab, and clinical remission was achieved again. Combination of daratumumab in the treatment of initial diagnosed acquired thrombotic thrombocytopenic purpura can rapidly restore ADAMST13 activity and turn negative for ADAMST13 inhibitors, resulting in long-term remission in patients.
- 13 January 2023
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 55 (2) , 399-405
Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia associated with disseminated microvascular platelet-rich thrombus. Before the introduction of plasma therapy, acute TTP was almost universally fatal, which improved survival from < 10 to 80–90%. However, patients who survived an acute attack were at high risk for recurrence and long-term morbidity. It was reported that daratumumab can eradicate persistent ADAMTS13-inhibiting autoantibodies and restore ADAMTS13 activity in two patients with relapsed immune-mediated TTP without associated adverse drug reactions. Here we report a case series of patients with initial diagnosed acquired TTP treated with combination regimens containing daratumumab. All the patients achieved clinical response after the initial treatment. Three patients achieved clinical remission, one patient relapsed and one patient suffered an exacerbation during follow-up. The two patients were retreated with glucocorticoids, plasma exchange combined with daratumumab, and clinical remission was achieved again. Combination of daratumumab in the treatment of initial diagnosed acquired thrombotic thrombocytopenic purpura can rapidly restore ADAMST13 activity and turn negative for ADAMST13 inhibitors, resulting in long-term remission in patients.